Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology II (PD49)1 Sep 2021PD49-08 CORRELATING IMMUNE CELL INFILTRATION PATTERNS WITH RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA Nicholas Chakiryan, Ali Hajiran, Youngchul Kim, Jad Chahoud, Philippe Spiess, Liang Wang, Carlos Moran-Segura, Jonathan Nguyen, Jasreman Dhillon, James Mule, and Brandon Manley Nicholas ChakiryanNicholas Chakiryan More articles by this author , Ali HajiranAli Hajiran More articles by this author , Youngchul KimYoungchul Kim More articles by this author , Jad ChahoudJad Chahoud More articles by this author , Philippe SpiessPhilippe Spiess More articles by this author , Liang WangLiang Wang More articles by this author , Carlos Moran-SeguraCarlos Moran-Segura More articles by this author , Jonathan NguyenJonathan Nguyen More articles by this author , Jasreman DhillonJasreman Dhillon More articles by this author , James MuleJames Mule More articles by this author , and Brandon ManleyBrandon Manley More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002071.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Clear cell renal cell carcinoma (ccRCC) tumors harbor comparatively low frequencies of genetic alterations yet very high levels of immune cell infiltration. Identifying associations between specific ccRCC somatic mutations and patterns of immune cell infiltration within the tumor immune microenvironment could be impactful in both research and clinical settings. METHODS: Pre-treatment tumor specimens were collected from 48 patients with metastatic ccRCC. Next-generation sequencing was performed using a 275-gene comprehensive cancer panel. Formalin-fixed paraffin-embedded tissue samples were then stained using 2 multiplex immunofluorescence (IF) panels to identify T cells (CD3, CD8, FOXP3, TBet) and myeloid cells (CD68, CD163, CD206). Using digital image analysis, immune cell marker densities were analyzed in 3 regions of interest (ROIs): the tumor core, the tumor-stroma interface, and the surrounding stroma. Using TCGA, CPTAC, and Moffitt TCC genomic data sources, enrichment scores for individual cell lines were determined from the sequencing panels using the xCell bioinformatic pipeline and compared with IF infiltration patterns. A linear mixed model analysis was performed to test associations between IF patterns and genetic alterations. Log-rank and multivariable Cox regression were used to analyze survival outcomes. RESULTS: Tissue from 24 primary tumors and 24 metastatic tumors were analyzed. The most frequent somatic mutations included VHL (79.1%), BAP1 (41.7%), SETD2 (41.7%), PBRM1 (35.4%), TP53 (18.8%), and KDM5C (16.7%). Overall, tumors with SETD2 mutations had significantly decreased levels of FOXP3+ T regulatory cells across all 3 ROIs. PBMR1 mutations were associated with decreased tumor core FOXP3+ T regulatory cells. KDM5C mutations were associated with significantly increased macrophage tumor infiltration (CD206+ and CD68+/206+). BAP1 mutated tumors had increased sequencing-derived macrophage enrichment scores in TCGA and CPTAC, and AVATAR, but without an associated increase in IF-detected macrophage infiltration in primary tumor samples for any ROI. On multivariable analysis, patients with SETD2 mutations had significantly worse overall survival (p <0.01) and survival following immunotherapy treatment (p <0.01). Patients with KDM5C had worse overall survival (p=0.02) and survival following immunotherapy (p=0.048). CONCLUSIONS: This study provides evidence that there are associations between somatic mutations, such as SETD2 and KDM5C, and macrophage and T cell infiltration patterns in the TIME in ccRCC. Sequencing-derived xCell enrichment scores from TCGA, CPTAC, and AVATAR were discordant with the IF-derived immune cell infiltration findings. These novel associations have the potential to inform precision research and immunotherapeutic treatment strategies. Source of Funding: N/A © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e847-e848 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nicholas Chakiryan More articles by this author Ali Hajiran More articles by this author Youngchul Kim More articles by this author Jad Chahoud More articles by this author Philippe Spiess More articles by this author Liang Wang More articles by this author Carlos Moran-Segura More articles by this author Jonathan Nguyen More articles by this author Jasreman Dhillon More articles by this author James Mule More articles by this author Brandon Manley More articles by this author Expand All Advertisement Loading ...

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Figure 4 from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Methods and Figures and Tables from the Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma

Supplementary Materials and Methods from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

PD49-08 CORRELATING IMMUNE CELL INFILTRATION PATTERNS WITH RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Additional File 1: of NR1B2 Suppress Kidney Renal Clear Cell Carcinoma (KIRC) Progression by Regulation of LATS 1/2-YAP Signaling

Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Methods and Data (posted 7/5/2011) from Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer

Supplementary Materials and Methods, Table 1, Figures 1 - 6 from SCP Phosphatases Suppress Renal Cell Carcinoma by Stabilizing PML and Inhibiting mTOR/HIF Signaling

Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Supplementary Table 1 from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Supplementary Data from Array-Based Comparative Genomic Hybridization Identifies <i>cdk4</i> and <i>foxm1</i> Alterations As Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor

Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators &lt;i&gt;bap1&lt;/i&gt; and &lt;i&gt;setd2&lt;/i&gt;: A Report by MSKCC and the KIRC TCGA Research Network